Alexander Hardy: Today, we’re commemorating a significant milestone at Genentech – the 25th anniversary of a groundbreaking medicine for patients with HER2+ metastatic breast cancer.
Quoting Alexander Hardy, Chief Executive Officer at Genentech, on LinkedIn:
“Today, we’re commemorating a significant milestone at Genentech – the 25th anniversary of a groundbreaking medicine for patients with HER2+ metastatic breast cancer. It was the first targeted treatment for solid cancer tumours, helping to usher in the revolutionary era of personalized medicine and fundamentally change how we fight cancer.
This milestone holds a special place in my heart, having led the Sales and Marketing team for the HER2+ Franchise. During my time in this role, I had the privilege of launching two additional medicines – adding to the arsenal in the fight against breast cancer – and the honor of witnessing the profound impact these life-altering scientific breakthroughs have had on the lives of our patients and their families.
While this is an opportunity to take stock of our progress, it’s also a reminder that far too many people are impacted by this disease. As we mark this milestone, let’s remember that our mission is about saving and improving lives. Here’s to the next 25 years of innovation, unwavering dedication to our patients and serving society.”
Source: Alexander Hardy/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023